Real-world safety of ixekizumab: a disproportionality analysis using the FDA adverse event reporting system and the VigiAccess databases
This study confirmed several known AEs and identified some unexpected AEs, providing preliminary safety insights to guide clinicians in the safe use of ixekizumab in clinical practice. It is important to note that findings from spontaneous adverse event reporting systems are hypothesis-generating and may be limited by underreporting, variable reporting quality, and confounding factors.
Authors
- Xiao-Xiang Tan
- Jiashu Liu
- Jing Li (ORCID: https://orcid.org/0000-0002-8030-7146)
- Qing Li (ORCID: https://orcid.org/0000-0002-4982-1024)
- Miao Qin
- Ying Liu (ORCID: https://orcid.org/0000-0002-8165-9143)
- Kaidi Zhao (ORCID: https://orcid.org/0000-0001-6716-3179)
- Q. C. Meng
Institutions
- Shanghai Jiao Tong University (CN)
- Xi'an Honghui Hospital (CN)
- Northwest Women's and Children's Hospital (CN)
- Second Affiliated Hospital of Xi'an Jiaotong University (CN)
- Xi’an Children’s Hospital (CN)
- Shanghai Sixth People's Hospital (CN)
Publication Details
- Journal
- Frontiers in Medicine
- Published
- 2025-10-13
- DOI
- https://doi.org/10.3389/fmed.2025.1652401
- Primary Topic
- Pharmacovigilance and Adverse Drug Reactions
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Natural Science Foundation of Shaanxi Province